Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 165

Sort by

Sort Order Select

Journal Articles

The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment

Blood (2023) 142 (10): 903–917.

https://doi.org/10.1182/blood.2022019537

Published: 2023

Includes: Supplemental data

Journal Articles

Molecular Profiles and Clinical Features of Myeloproliferative Neoplasms Unclassifiable (MPN-U) with and without JAK2 / CALR / MPL Mutations

Curtis Gravenmier, Yumeng Zhang, Nagehan Pakasticali, Lynn C. Moscinski, Jinming Song, Ling Zhang

Blood (2022) 140 (Supplement 1): 12248–12249.

https://doi.org/10.1182/blood-2022-170665

Published: 2022

Journal Articles

The Prognostic Impact of FLT3 in NPM1 -Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes

Onyee Chan, Najla Al Ali, Somedeb Ball, Justin Grenet, Caroline Hana, Yehuda E. Deutsch, Hammad Tashkandi, Ling Zhang, Mohammad O Hussaini, Seongseok Yun, Andrew Kuykendall, Eric Padron, Gail J. Roboz, Pinkal Desai, Rami S. Komrokji, Kendra Sweet, Jeffrey E. Lancet, David A. Sallman

Blood (2022) 140 (Supplement 1): 3435–3437.

https://doi.org/10.1182/blood-2022-171197

Published: 2022

Journal Articles

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

Blood (2022) 140 (Supplement 1): 3419–3421.

https://doi.org/10.1182/blood-2022-165802

Published: 2022

Journal Articles

XPO1 Overexpression Is a Mechanism of Resistance to Eprenetapopt and 5-Azacitidine Therapy That Can be Therapeutically Exploited for the Treatment of TP53 Mutated Myeloid Malignancies

Traci L. Kruer, Ariel Quintana, Meghan Ferrall-Fairbanks, Ling Zhang, Hannah Newman, Amy F McLemore, Qin Yang, Nana Bencrentsil, Rami S. Komrokji, Sana Chaudhry, Tulasigeri M Totiger, Maria Ken E. Figueroa, Justin Taylor, David A. Sallman, Eric Padron

Blood (2022) 140 (Supplement 1): 99–100.

https://doi.org/10.1182/blood-2022-169765

Published: 2022

Journal Articles

Autologous Hematopoietic Cell Transplant Consolidation for First Response Is Associated with Longer Survival in Patients with Nodal Peripheral T-Cell Lymphoma

Yumeng Zhang, Ashley Rose, Jennifer Eatrides, Hayder Saeed, Bijal D. Shah, Aleksandr Lazaryan, Farhad Khimani, Javier Pinilla Ibarz, Hien D. Liu, Frederick L. Locke, Michael D. Jain, Mohamed A. Kharfan-Dabaja, Jongphil Kim, Ling Zhang, Ernesto Ayala, Taiga Nishihori, Lubomir Sokol

Blood (2022) 140 (Supplement 1): 6569–6570.

https://doi.org/10.1182/blood-2022-168347

Published: 2022

Journal Articles

Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma

Yumeng Zhang, Jennifer Eatrides, Ashley Rose, Ling Zhang, Farhad Khimani, Aleksandr Lazaryan, Bijal D. Shah, Hayder Saeed, Michael D. Jain, Hien D. Liu, Frederick L. Locke, Javier Pinilla Ibarz, Jongphil Kim, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Lubomir Sokol, Taiga Nishihori

Blood (2022) 140 (Supplement 1): 10634–10636.

https://doi.org/10.1182/blood-2022-169200

Published: 2022

Journal Articles

Immunohistochemical Analysis of Inflammasome Signaling Component Expression Among Patients with Low Risk and High Risk Myelodysplastic Syndrome Using Tissue Microarray

Tony J Kurian, Kathy McGraw, Sanjay Bridgelall, Rohit Sharma, Qianxing Mo, Wenyi Fan, Jeffrey E. Lancet, Rami S. Komrokji, Seongseok Yun, Ling Zhang

Blood (2021) 138 (Supplement 1): 4648.

https://doi.org/10.1182/blood-2021-150137

Published: 2021

Journal Articles

Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1 -Mutated ELN Favorable Risk AML

Onyee Chan, Najla Al Ali, Hammad Tashkandi, Austin Ellis, Somedeb Ball, Ling Zhang, Mohammad Hussaini, Jinming Song, Seongseok Yun, Chetasi Talati, Andrew T. Kuykendall, Eric Padron, David A. Sallman, Kendra Sweet, Rami S. Komrokji, Jeffrey E. Lancet

Blood (2021) 138 (Supplement 1): 686.

https://doi.org/10.1182/blood-2021-150759

Published: 2021

Journal Articles

Upfront Targeted Tyrosine Kinase Inhibitor Therapy Improves Outcome in Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia

Yumeng Zhang, Chuanyi M. Lu, Endi Wang, Lynh Nguyen, Marietya Lauw, Somedeb Ball, Ning C. Dong, Lynn C. Moscinski, Onyee Chan, Seongseok Yun, Lubomir Sokol, Bijal D. Shah, Jeffrey E. Lancet, Andrew T. Kuykendall, Eric Padron, Ling Zhang

Blood (2021) 138 (Supplement 1): 3658.

https://doi.org/10.1182/blood-2021-151654

Published: 2021

Journal Articles

Clinical Features and Treatment Outcomes of Large Granular Lymphocytic Leukemia Coexisting with Autoimmune Diseases

Ning Dong, Franco Castillo Tokumori, Leidy Isenalumhe, Yumeng Zhang, Ankita Tandon, Todd C. Knepper, Haipeng Shao, Ling Zhang, Lubomir Sokol

Blood (2021) 138 (Supplement 1): 1391.

https://doi.org/10.1182/blood-2021-151477

Published: 2021

Journal Articles

Two Distinct Clinical Courses and Outcomes in T-Cell Prolymphocytic Leukemia

Ashley Rose, Akriti G Jain, Hayder Saeed, Lubomir Sokol, Ling Zhang, Xiaohui Zhang

Blood (2021) 138 (Supplement 1): 1389.

https://doi.org/10.1182/blood-2021-150672

Published: 2021

Journal Articles

High MYC Expression Predicts Poor Survival Outcomes in IDH1/2 Mutant AML Patients

Virginia Olivia Volpe, Nicole D. Vincelette, Onyee Chan, Chetasi Talati, Kendra Sweet, Andrew T. Kuykendall, Constantine Logothetis, Rami S. Komrokji, Gregoire Calon, Nathan P. Horvat, David A. Sallman, Eric Padron, Ling Zhang, Seongseok Yun

Blood (2021) 138 (Supplement 1): 2377.

https://doi.org/10.1182/blood-2021-147030

Published: 2021

Journal Articles

C-MYC Augments the Proliferation and Survival of Hematopoietic Stem Cells and Multipotent Progenitors to Drive Myeloproliferative Neoplasms

Nicole D. Vincelette, Jungwon Moon, Andrew T. Kuykendall, Ling Zhang, Rami S. Komrokji, Daniel Murphy, John L. Cleveland, Seongseok Yun

Blood (2021) 138 (Supplement 1): 28.

https://doi.org/10.1182/blood-2021-146399

Published: 2021

Journal Articles

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Blood (2021) 138 (Supplement 1): 246.

https://doi.org/10.1182/blood-2021-153286

Published: 2021

Journal Articles

Tfeb Links MYC Signaling to Epigenetic Control of Acute Myeloid Leukemia Cell Death and Differentiation

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-137209

Published: 2020

Journal Articles

Large Granular Lymphocytic Leukemia with Coexisting Malignancies

Ning Dong, MD, Leidy Isenalumhe, MD, Yumeng Zhang, MD, Franco Castillo Tokumori, MD, Todd C. Knepper, PharmD, Rami Komrokji, MD, Ling Zhang, MD, Haipeng Shao, MD, Lubomir Sokol, MD PhD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136796

Published: 2020

Journal Articles

Outcomes of Front-Line Therapy for Adult T Cell Leukemia/Lymphoma: A Pooled Analysis of Two Institutions

Jose Sandoval-Sus, MD, Franco Castillo Tokumori, MD, Ning Dong, MD, Stephanie Boisclair, MD, Amanda Brahim, PharmD, Damaal Walker, PharmD, Sanjay Bridgelall, MD, Ling Zhang, MD, Hayder Saeed, MD, Lubomir Sokol, MD PhD

Blood (2020) 136 (Supplement 1): 25.

https://doi.org/10.1182/blood-2020-140070

Published: 2020

Journal Articles

Clinical Characteristics and Outcomes of Patients with Large Granular Lymphocytic Leukemia Treated with Methotrexate, Cyclophosphamide or Cyclosporine. a Large Single Institutional Retrospective Analysis

Ankita Tandon, DO, Ning Dong, MD, Yumeng Zhang, MD, Emilie Wang, MD, Todd C. Knepper, PharmD, Haipeng Shao, MD, Ling Zhang, MD, Leidy Isenalumhe, MD, Rami Komrokji, MD, Lubomir Sokol, MD PhD

Blood (2020) 136 (Supplement 1): 36–38.

https://doi.org/10.1182/blood-2020-141701

Published: 2020

Journal Articles

Molecular Insights into Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasm in Patients with Multiple Myeloma and Cytopenia(s)

Jinming Song, MD PhD, Hailing Zhang, MD, Xiaohui Zhang, MD PhD, Mohammad Hussaini, MD, Ning Dong, MD, Lynn C Moscinski, Kenneth H. Shain, MD PhD, Melissa Alsina, MD, Taiga Nishihori, MD, Ling Zhang, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141656

Published: 2020

NARROW

The non-cell-autonomous function of ID1 promotes AML progression via ANGPTL7 from the microenvironment

Molecular Profiles and Clinical Features of Myeloproliferative Neoplasms Unclassifiable (MPN-U) with and without JAK2 / CALR / MPL Mutations

The Prognostic Impact of FLT3 in NPM1 -Mutated AML: Co-Occurrence of FLT3-ITD and FLT3-TKD Confers Poor Outcomes

Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1 -Mutated AML

XPO1 Overexpression Is a Mechanism of Resistance to Eprenetapopt and 5-Azacitidine Therapy That Can be Therapeutically Exploited for the Treatment of TP53 Mutated Myeloid Malignancies

Autologous Hematopoietic Cell Transplant Consolidation for First Response Is Associated with Longer Survival in Patients with Nodal Peripheral T-Cell Lymphoma

Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma

Immunohistochemical Analysis of Inflammasome Signaling Component Expression Among Patients with Low Risk and High Risk Myelodysplastic Syndrome Using Tissue Microarray

Mutations Highly Specific for Secondary AML Are Associated with Poor Outcomes in Patients with NPM1 -Mutated ELN Favorable Risk AML

Upfront Targeted Tyrosine Kinase Inhibitor Therapy Improves Outcome in Patients with Myeloid/Lymphoid Neoplasms with Eosinophilia

Clinical Features and Treatment Outcomes of Large Granular Lymphocytic Leukemia Coexisting with Autoimmune Diseases

Two Distinct Clinical Courses and Outcomes in T-Cell Prolymphocytic Leukemia

High MYC Expression Predicts Poor Survival Outcomes in IDH1/2 Mutant AML Patients

C-MYC Augments the Proliferation and Survival of Hematopoietic Stem Cells and Multipotent Progenitors to Drive Myeloproliferative Neoplasms

Long Term Follow-up and Combined Phase 2 Results of Eprenetapopt (APR-246) and Azacitidine (AZA) in Patients with TP53 mutant Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia (AML)

Tfeb Links MYC Signaling to Epigenetic Control of Acute Myeloid Leukemia Cell Death and Differentiation

Large Granular Lymphocytic Leukemia with Coexisting Malignancies

Outcomes of Front-Line Therapy for Adult T Cell Leukemia/Lymphoma: A Pooled Analysis of Two Institutions

Clinical Characteristics and Outcomes of Patients with Large Granular Lymphocytic Leukemia Treated with Methotrexate, Cyclophosphamide or Cyclosporine. a Large Single Institutional Retrospective Analysis

Molecular Insights into Clonal Hematopoiesis and Therapy-Related Myeloid Neoplasm in Patients with Multiple Myeloma and Cytopenia(s)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only